Aperio Group’s Audentes Therapeutics, Inc BOLD Stock Holding History

Aperio Group’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,228	Closed	-$46K	–	2992
2019 Q2	$46K	Buy	+1,228	New	+$47.2K	﹤0.01%	2552

Other funds holding BOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Aperio Group's BOLD Position: Q3 2019 in Review

Aperio Group sold out of Audentes Therapeutics, Inc (BOLD) in Q3 2019, closing a stake of 1,228 shares — an estimated $46K sold.

Aperio Group first reported a position in BOLD in Q2 2019 and held it in 1 quarter. The position peaked at $46K in Q2 2019. 149 funds tracked by Wall St. Rank hold BOLD as of Q3 2019.

Aperio Group reported no remaining Audentes Therapeutics, Inc position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 1,228 Audentes Therapeutics, Inc shares in Q3 2019, an estimated $46K.
Aperio Group first reported a position in Audentes Therapeutics, Inc in Q2 2019 and held it in 1 quarter.
Aperio Group's Audentes Therapeutics, Inc position peaked at $46K in Q2 2019.
149 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.